Ford Motor Co
Change company Symbol lookup
Select an option...
F Ford Motor Co
CPB Campbell Soup Co
T AT&T Inc
GSS Golden Star Resources Ltd
TBNK Territorial Bancorp Inc
YUM Yum! Brands Inc
RTX Raytheon Technologies Corp
NAKD Naked Brand Group Ltd
FAMI Farmmi Inc
PTPI Petros Pharmaceuticals Inc

Consumer Discretionary : Automobiles | Large Cap Blend
Company profile

Ford Motor Company is an automobile company that designs, manufactures, markets, and services a full line of Ford trucks, utility vehicles, cars as well as Lincoln luxury vehicles. The Company operates in three segments: Automotive, Mobility and Ford Credit. The Automotive segment is engaged in developing, manufacturing, distributing, and servicing the vehicles, parts and accessories of Ford and Lincoln vehicles. The Mobility segment primarily includes the development of Ford’s autonomous vehicles and related businesses. The Company also holds ownership is Argo AI, which is a developer of autonomous driving systems, and Spin, which is a micro-mobility service provider. The Ford Credit segment is comprised of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. Ford Credit offers a wide variety of automotive financing products to and through automotive dealers throughout the world.

Closing Price
Day's Change
-0.73 (-3.67%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Lightstone Ventures Raises $375 Million Fund

7:00 am ET September 14, 2021 (PR Newswire) Print

Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and technologies that have the potential to change patients' lives. The new fund was oversubscribed, exceeding the firm's targeted raise, and included strong support from both new and existing limited partners. With the closing of Fund III, Lightstone Ventures also announced the appointments of Christina Isacson, Ph.D., as Partner and Young Kwon, Ph.D., as Operating Partner.

"We are very excited for the future of Lightstone and the important work that this new fund will enable," said Mike Carusi, General Partner at Lightstone. "Our investment philosophy is guided by a commitment not just to exciting ideas but to the people leading them forward. This is an important moment for the firm that builds upon the successes we have had with our previous two funds and the companies we have invested in that are already making an impact on patients. We look forward to continuing our partnership with driven entrepreneurs developing therapies and technologies that have the potential to be industry-leading products."

Since its inception in 2012, Lightstone has invested in more than 30 companies, all of which share a commitment to translating scientific breakthroughs into clinically and commercially meaningful therapies and technologies. In addition to venture capital experience, Lightstone's senior investment team brings significant operational leadership experience, enabling the firm to collaborate with founders to establish strategies that transform their visions into commercially viable products. Lightstone has a global presence, with offices in Menlo Park, Calif., Boston, Mass., Singapore, and Dublin, Ireland. The team includes:

-- Mike Carusi, General Partner

-- Jean George, General Partner

-- Jason Lettmann, General Partner

-- Hanson S. Gifford, III, Partner

-- Christina Isacson, Ph.D., Partner

-- Caroline Gaynor, Principal

-- Hank Plain, Special Partner

-- Mark Deem, Operating Partner

-- Young Kwon, Ph.D., Operating Partner

-- Stacy Enxing Seng, Operating Partner

-- Kenneth D. Noonan, Ph.D., CEO, Lightstone Singapore PTE. LTD.

-- Travis Boettner, CFO & CCO

The Lightstone team has raised over $850 million since inception and has invested in companies such as Alchemab Therapeutics, ALX Oncology (NASDAQ: ALXO), Catamaran Bio, Cyteir Therapeutics (NASDAQ: CYT), Claret Medical (Acquired by Boston Scientific), Disarm Therapeutics (Acquired by Eli Lilly and Co.), Gemini Therapeutics (NASDAQ: GMTX), LocanaBio, Nimbus, Ra Pharma (Acquired by UCB), Tizona (Acquired by Gilead Sciences), and Willow.

"With Lightstone Ventures III, we look forward to empowering visionary entrepreneurs who are changing medicine, providing the same high-touch collaboration that founders have come to expect from our team along with increased financial resources," said Jason Lettmann, General Partner at Lightstone Ventures. "In addition, we are delighted to welcome Christina and Young to the team. One of Lightstone's key differentiators is our ability to leverage our team's leadership experience to provide hands-on guidance to the founders and teams we support. Both Christina and Young have held multiple C-suite level leadership roles, and they bring significant operational experience that will prove incredibly valuable to our portfolio companies."

Dr. Isacson has spent over 16 years in the biotechnology industry and brings experience creating, launching, building and operating public and private biotech companies. Prior to joining Lightstone, she was a member of the founding team and Chief Business Officer at Magenta Therapeutics, and a part of the founding team at Decibel Therapeutics. She also has extensive experience in venture capital, most recently with Third Rock Ventures. Dr. Isacson holds a Ph.D. in Neuroscience from Tufts University School of Medicine, Graduate School of Biomedical Sciences, as well as a B.Sc. in Biology from McGill University.

Dr. Kwon is a proven executive with significant operating and venture capital experience, and specializes in deal sourcing, due diligence, and portfolio company management. He has held a variety of leadership roles with over ten years as a C-suite executive at Momenta Pharmaceuticals, a public biotech company, prior to its sale to Johnson & Johnson for $6.5 billion. He holds a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University, as well as a B.S. in Biology from the Massachusetts Institute of Technology.

About Lightstone Ventures

Lightstone Ventures is a global venture capital firm investing in biotech and medtech companies pioneering big ideas poised to transform patient outcomes. We were founded in 2012 to empower visionary entrepreneurs with the resources and operational guidance necessary to bring their innovative therapeutics and technologies to the patients who need them most. Our investment team has led deals resulting in 19 acquisitions and 20 initial public offerings over the last two decades. The firm has offices in Boston, Mass., Menlo Park, Calif., Dublin, Ireland and Singapore.

For more information, please visit

View original content:

SOURCE Lightstone Ventures

comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.